Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:40:37 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



News for U:ABUS from 2023-05-04 to 2024-05-03 - 37 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-02 17:42U:ABUSSEDAR Interim MD & ASEDAR Interim MD & A
2024-05-02 17:21U:ABUSSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-05-02 07:30U:ABUSNews ReleaseArbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-05-02 07:25U:ABUSNews ReleaseArbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
2024-04-18 07:30U:ABUSNews ReleaseArbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
2024-04-04 08:31U:ABUSNews ReleaseArbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
2024-03-08 07:30U:ABUSNews ReleaseArbutus to Participate in Two Upcoming Investor Conferences
2024-03-06 13:11U:ABUSSEDAR MD & ASEDAR Annual Report
2024-03-06 12:36U:ABUSSEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2024-02-29 07:30U:ABUSNews ReleaseArbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
2024-02-15 07:30U:ABUSNews ReleaseArbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
2024-01-08 07:30U:ABUSNews ReleaseArbutus Announces 2024 Corporate Objectives and Provides Financial Update
2023-11-09 16:25U:ABUSNews ReleaseBarinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
2023-11-09 16:01U:ABUSNews ReleaseArbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting ‚ ®
2023-11-08 07:30U:ABUSNews ReleaseArbutus to Present at Jefferies London Healthcare Conference
2023-11-07 18:16U:ABUSSEDAR Interim MD & ASEDAR Interim MD & A
2023-11-07 18:12U:ABUSSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-11-07 07:30U:ABUSNews ReleaseArbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-11-07 07:15U:ABUSNews ReleaseArbutus Announces CEO, William Collier, to Retire December 31, 2023
2023-10-24 07:30U:ABUSNews ReleaseArbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
2023-10-18 07:30U:ABUSNews ReleaseArbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
2023-10-11 08:05U:ABUSNews ReleaseArbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting ‚ ® 2023
2023-09-11 16:15U:ABUSNews ReleaseArbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended
2023-09-07 07:30U:ABUSNews ReleaseArbutus to Participate in Two Upcoming Investor Conferences
2023-08-04 09:27U:ABUSSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-08-03 07:30U:ABUSNews ReleaseArbutus Reports Second Quarter 2023 Financial Results and ‚  Corporate Update
2023-07-20 07:30U:ABUSNews ReleaseArbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update
2023-07-12 07:30U:ABUSNews ReleaseArbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
2023-07-10 16:01U:ABUSNews ReleaseArbutus Appoints Two New Executives
2023-06-21 07:30U:ABUSNews ReleaseArbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
2023-06-21 02:01U:ABUSNews ReleaseArbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
2023-06-07 02:01U:ABUSNews ReleaseArbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
2023-05-31 07:30U:ABUSNews ReleaseArbutus to Present at Jefferies Healthcare Conference
2023-05-09 07:30U:ABUSNews ReleaseArbutus to Present at JMP Securities Life Sciences Conference
2023-05-04 17:37U:ABUSSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-05-04 17:36U:ABUSSEDAR MD & ASEDAR MD & A
2023-05-04 07:30U:ABUSNews ReleaseArbutus Reports First Quarter 2023 Financial Results and Corporate Update